TAS-102 and Inhibition of Poly (ADP) Ribose Polymerase as Maintenance Treatment for Advanced TP53 Mutant Ductal Adenocarcinoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Feb 2025 New trial record
25 Feb 2025 According to National Comprehensive Cancer Network media release, Christos Fountzilas, MD, FACP,Roswell Park Comprehensive Cancer Center is investigator of this trial.
25 Feb 2025 According to National Comprehensive Cancer Network media release, new funding aimed at advancing clinical research in gastrointestinal cancers. Three grants have been awarded to innovative investigator-initiated research to explore the potential of tipiracil/trifluridine (FTD/TPI) and/or futibatinib in treating gastrointestinal cancers. The initiative is made possible through a research grant provided by Taiho Oncology, Inc.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com